They emphasised organic, unprocessed, freshly prepared, and home-cooked food from local sources when possible
Semaglutide : FDA-approved since 2017
We selected these trials due to their similarities in assessing patients with both obesity and T2D, treatment duration, clinical development phase (phase 3), and use of semaglutide as an active treatment arm
The tissue usually recovers, but continued injection into affected areas makes it worse
C., Maguire, B., and Lake, J
Markus Rohrwild, Gubra CEO March 13, 2026 11:21 AM EDTUpdated 03:18 PM Startups Danish biotech Gubra plots Roivant-like model to churn out new companies Kyle LaHucik Biotech Correspondent A 300-employee Danish biotech is evolving beyond its obesity partnerships and looking to adopt an incubation model that has served Roivant Sciences quite well over Sign up to read this article for free